1	Title: Artificial Intelligence Algorithms in Nailfold
2	Capillaroscopy Image Analysis: A Systematic Review
3	
4	Author list: Omar S. Emam ^{1*} ; Mona Ebadi Jalal ^{1,2} , Begonya Garcia-Zapirain ³ , Adel S.
5	Elmaghraby ^{1,2}
6	1. Hive AI Innovation Studio, University of Louisville, KY, US
7	2. Department of Computer Science and Engineering, University of Louisville, KY, US
8	3. eVida Lab, Faculty of Engineering, University of Deusto, Bilbao, Spain
9	
10	*Corresponding Author: Omar S. Emam
11	Hive AI Innovation Studio, University of Louisville, Louisville, Kentucky, US
12	Email: <u>osemam01@louisville.edu</u> Alternative Email: <u>omarsamehemam@gmail.com</u>
13	
14	Author Contributions: OSE and MEJ performed systematic search, study selection, data
15	curation and extraction. BGZ (Co-PI) and ASE (PI) supervised and guided the flow process,
16	ensured validation and quality of the manuscript, and were resorted to in cases of inter-author
17	disagreement. All four authors were involved in conceptualization, writing, review and editing.
18	
19	Running Title: A Systematic review on AI in nailfold capillaroscopy
20	Keywords: Artificial Intelligence, Machine Learning, Deep Learning, Nailfold
21	Capillaroscopy, Video-capillaroscopy, Microscopic Angioscopy.
22	Financial Disclosure Statement: None of the authors have any conflicts of interest.

23 ABSTRACT

Background Non-invasive imaging modalities offer a great deal of clinically significant information that aid in the diagnosis of various medical conditions. Coupled with the neverbefore-seen capabilities of Artificial Intelligence (AI), uncharted territories that offer novel innovative diagnostics are reached. This systematic review compiled all studies that utilized AI in Nailfold Capillaroscopy as a future diagnostic tool.

Methods and Findings Five databases for medical publications were searched using the 29 keywords artificial intelligence, machine learning, deep learning and nailfold capillaroscopy to 30 return 105 studies. After applying the eligibility criteria, 10 studies were selected for the final 31 analysis. Data was extracted into tables that addressed population characteristics, AI model 32 development and nature and results of their respective performance. We found supervised deep 33 learning approaches to be the most commonly used (n = 8). Systemic Sclerosis was the most 34 commonly studied disease (n = 6). Sample size ranged from 17,126 images obtained from 289 35 participants to 50 images from 50 participants. Ground truth was determined either by experts 36 labelling (n = 6) or known clinical status (n = 4). Significant variation was noticed in model 37 training, testing and feature extraction, and therefore the reporting of model performance. Recall, 38 39 precision and Area Under the Curve were the most used metrics to report model performance. Execution times ranged from 0.064 to 120 seconds per image. Only two models offered future 40 predictions besides the diagnostic output. 41

42 Conclusions AI has demonstrated a truly remarkable potential in the interpretation of Nailfold
43 Capillaroscopy by providing physicians with an intelligent decision-supportive tool for improved

diagnostics and prediction. With more validation studies, this potential can be translated to dailyclinical practice.

46 **1 INTRODUCTION**

47 Capillaries are the tiniest and most numerous blood vessels that link the body's arterial system to its venous system. They branch superficially and deeply into all body tissues to 48 provide nutrients and remove waste products (1, 2). This healthy microenvironment can get 49 50 severely dysfunctional due to the pathological processes in numerous abnormal conditions (3); 51 for example: a) systemic diseases such as diabetes (4, 5), or metabolic syndrome, b) auto-52 immune inflammatory pathologies such as vasculitis and dermatomyositis (6), and c) connective 53 tissue diseases (7) such as systemic sclerosis (SSc) (8, 9) systemic lupus erythematosus (10, 11), and Raynaud's phenomenon (12, 13). Capillaries in the retina, tongue, or nailfolds provoke a 54 particular medical interest due to their ease of accessibility and examination using common non-55 invasive tools that yield clinically significant information. In other words, the diagnosis and 56 57 follow up of internal systemic conditions can be performed without the need to resort to invasive 58 approaches.

Nailfold Capillaroscopy (NFC), which is a type of microscopic angioscopy, is a 59 technique of visualizing the capillaries in the nailfold area (14). It examines the ultimate 60 61 capillary endings in the finger as capillaries loop to turn back around. To visualize these terminal capillaries in that thin layered area of the skin, the subject as well as the surrounding 62 environment are prepared and then a microscopic lens can be used to directly observe the 63 capillaries. Nailfold Video Capillaroscopy (NVC) (15, 16)uses a more advanced scope with a 64 camera that offers far superior resolution, clarity, and the ability to record a video and take 65 photos (6). These images are then analyzed by trained experts to differentiate normal healthy 66

capillaries from faulty pathological ones according to certain specific criteria. This information
can aid in diagnosis, progression and severity assessment (17), disease staging (18-22), followup and perhaps prediction of certain medical conditions. Unfortunately, such convenient classical
methods of manual analyses imply subjectivity, prolonged analyses time, and ambiguity of
findings (23-25).

72 The recent trends utilizing Artificial Intelligence (AI), especially in medicine and biomedical sciences, seem to offer a highly sought-after outturn as a superior alternative (26, 27). 73 74 To illustrate, many deep learning models have demonstrated the ability to objectively analyze 75 images from NFC/NVC with higher, or at least comparable, efficiency as capillaroscopy experts in a significantly lower time (5, 15, 28-41). Advances in computer vision algorithms allow the 76 extraction, quantification, and accurate analysis of far more features compared to human experts. 77 These innovations present an unprecedented potential to link a multitude of variables to diseases 78 79 and, consequently, draw future predictions (7). The information gained from such technology 80 would be crucial to inform decisions concerning patient education and treatment in many ways. For example, predictive models can be used as an adjunct screening tool, diagnostic tools can 81 help accelerate clinical work, establish risk stratification, and reduce rates of misdiagnoses (42). 82 83 Moreover, the smart 'learning' nature of these tools will benefit from feedback and provide explanations to further improve their accuracy (43). As such, these innovations claim the 84 85 potential to transform existing medical practices by enhancing the decision-making process using 86 such tools. In other words, is it practically feasible to improve the quality of care delivered to 87 patients using such cheap, easy, non-time-consuming means?

In this systematic review, we aim to give an overview on the state-of-the-art by compiling all studies, to date, that utilized an AI algorithm to analyze output from NFC/NVC as

a tool to be used clinicians in medical practice. We describe the methodology used to conduct a
comprehensive search of the literature to encompass all novel studies addressing this topic. Next,
we presented the summarized results of the included reports. Finally, we divided the discussion
into four sections to organize the gathered evidence to answer our research questions with
commentary on a few important issues as follows: Section I: a brief background on the
significance of NFC in medicine, Section II: Challenges facing the manual method, Section III:
How AI is solving these challenges, and finally Section IV: Future directions and limitations.

97

98 2 METHODS

99 This systematic review was conducted in compliance with the Preferred Reporting Items 100 for Systematic Reviews and Meta-Analysis (PRISMA) (44). We formulated the research 101 questions, and explained their significance, in **Table 1**, to guide the following search and 102 screening steps.

103

Table 1. Research questions and their rationale

	Research Question	Rationale
Q1	Can AI successfully detect clinically significant changes in NFC images?	To ensure that the information captured is relevant and useful to clinicians
Q2	Is pre-analysis processing required for an optimized output?	To check the user-friendliness and practically consider the time elapsed
Q3	Is there a minimum number of variables/features to be extracted for an accurate enough output?	To understand how these algorithms work and study the "significant" variables/features
Q4	Is information from NFC/NVC alone enough? Or is combining them with other diagnostic modalities and data sources needed?	To maximize the potential for detection, data acquisition and interpretation
Q5	Would the "early' use of such technologies help in predicting future outcomes?	To consider the possibility of early interventions and thus better patient reported outcomes
Q6	What conditions/diseases can this technology be applied to?	To understand the scope and generalizability or individuality of these AI applications

105 **2.1 Data Collection**

106 2.1.1 Search Strategy

We performed an all-time search on December 14th, 2023, that was later updated in 107 March 2024, utilizing five electronic medical databases: PubMed (including MEDLINE), 108 EMBASE, CINAHL, and Web of Science using the keywords: "Nailfold", "Capillaroscopy", 109 "Artificial Intelligence", "Machine Learning" and "Deep Learning" to generate the search 110 string: (nail OR nailfold OR "nail-fold") AND (capillaroscopy OR "video capillaroscopy" OR 111 NVC OR "microscopic angioscopy" OR onychoscopy) AND ("artificial intelligence" OR AI OR 112 "machine learning" OR "deep learning" OR algorithm*). MeSH terms and boolean operators 113 114 were used where appropriate. Fig.1 shows a PRISMA flow diagram that summarizes the 115 searching process.

116

117 **2.1.2 Inclusion and Exclusion Criteria**

We limited the search results to availability of full texts in the English language through our institutional access. We included all 1) peer reviewed journal articles, 2) both qualitative and quantitative studies, 3) that presented an AI model, 4) to analyze NFC/NVC images, and 5) was internally validated or tested on a real dataset.

We excluded unpublished data under review, conference abstracts and proceedings, and grey literature such as short surveys, and letters to editors. Additionally, we excluded studies that 1) utilized a purely mathematical model/algorithm that is not categorized as AI, or 2) presented technical aspects of the technology without applying it to a real data set as a diagnostic or prognostic tool, or 3) included other techniques to study the nailfold capillaries other than NFC such as optoacoustic imaging or ultrasound, whether independently or in fusion with NFC.





129

130 **2.1.3 Study Selection and Data Extraction Process**

Two authors independently performed the search and imported the results to the EndNote v.20 reference manager, where duplicates were removed. Any conflicting judgements were resolved by a third author. We then extracted data related to the study design, target population

characteristics and sampling, pre-procedural setting description, pre-analysis processing, AI
methods, model training and development, type of input and output, performance metrics,
limitations, strengths, and finally conclusions; that process was repeated for all final ten studies
included in the review.

138

139 **2.2 Quality Assessment and Risk of Bias**

Assessment of quality and the risk of bias in diagnostic accuracy studies is commonly 140 done using known validated tools such as STARD (45) and QUADAS (46), or tools like 141 TRIPOD (47) for prognostic studies as well. However, the novel nature of AI-related studies 142 created a demand for more relevant and appropriately updated tools that many authors sought to 143 144 meet by modifying or adding extensions to the aforementioned tools such as QUADAS-AI (48), STARD-AI (49), and TRIPOD-AI (50). Unfortunately, these tools are still under development 145 analysis and there is currently no agreed upon gold standard tool to be used (51). For these 146 147 reasons we opted to refer to the updated QUADAS-2 tool (52) and complement the assessment with the MINIMAR (53) and CAIR (54) tools that present a checklist for reporting AI studies to 148 149 healthcare providers, as outlined in supplementary document S1.

150 **3 RESULTS**

151	The search process returned 105 results that were then screened by title, abstract, and
152	finally after full-text reading using the eligibility criteria to arrive at the final list of ten studies as
153	summarized in Fig. 1 (15, 28-32, 35, 40, 41, 55). Six out of the ten studies were published within
154	a year of writing this manuscript (in 2023) illustrating the novelty of the topic at hand (28-31, 41,
155	55). The geographical distribution of countries where these studies were conducted is shown in
156	Fig. 1. The following



Fig. 1 Geographical distribution of the countries of included studies

157 **Table 2** shows a summary of the main highlights of all ten studies including population

158 characteristics.

159

Table 2. A summary of the main highlights and population characteristics of all ten studies.

			Target]	Population Chara	acteristics		AIMG	del
Autuor and Year	Country	Diseases addressed	Disease Duration	Database	Sample size	No. of Participants	Nature of Task	Detection Time
Yin et al 2023 (28)	China	HC only	I	N/A	1,788 images	30	DL -Capillary Segmentation	0.064 sec /image
Shah et al 2023 (55)	Canada	DM, complications* & HC	≥ 10 years	Boris Clinic at Hamilton Health Sciences	5,236 images	120 = 60 HC + 60 DM	DL - Classification	I
Garaiman et al 2023 (30)	Switzerland	SSc of varying severities	I	Local registries EUSTAR & VEDOSS	17,126 images	289	DL - Classification	0.19 secs /image
Bharati et al 2023 (31)	UK	Early SSC, PRD & HC	I	Salford Royal NHS Foundation Trust, a 3ry referral center	2,541 mosaics = 2,117 Hi-res (A &B) + 424 low-res (C)	309 = 155 SSc + 154 HC/PRD	DL - Mixed	I
Kassani et al 2023 (41)	US	aJDM & HC	3-33 years	JDM clinic of Lurie Children's Hospital of Chicago	Diagnostic: 1,441 images & Predictive: 1,760 images	142 = 111 aJDM + 31 HC	DL - Classification	I
Tello et al 2023 (29)	Spain	PRD,& SRP		5 Spanish hospitals	1,164 images	l	DL - Mixed	I
Tello et al 2022 (15)	Spain	PRD,& SRP	I	Built from 9 Spanish 3 ¹⁷ hospitals (members of GEAS, SEMI & SEMIAS)	2,713 images with >18k measurements	I	DL - Mixed	I
Liu et al 2020 (32)	China	Htn & HC	I	N/A	50 **	60	DL - pixel Segmentation	I
Berks et al 2014 (35)	UK	Severe SSC, PRD & HC	l	3 ^{ry} referral center for SSc Patients	990 mosaics	I	ML - Mixed	I
Murray et al 2011 (40)	UK	SSC (LC, DC), PRD & HC	I	N/A	116 mosaics	116 = 46 HC + 21 PRD + 49 SSc	ML - Classification	2 min /image

ML = Machine Learning, DL = Deep learning, N/A = No available data or not reported by author, HC = Healthy
 Controls, DM = Diabetes Mellitus, PRD = Primary Raynaud's Disease, SRP = Secondary Raynaud's Phenomenon,
 SSc = Systemic Sclerosis, LC = Limited Cutaneous, DC = Diffuse Cutaneous, aJDM = Active Juvenile
 Dermatomyositis, Htn = Hypertension *Complications include: Cardiovascular event, retinopathy, albuminuria and
 hypertension, ** used data augmentation to generate 20,664 samples from the original 50.

165 Synthesis of Evidence

166 **3.1 Study Designs**

167 Consistent with most diagnostic accuracy studies, all ten investigators adopted a 168 non-experimental cross-sectional design with case-control selection (15, 28-32, 35, 40, 41, 55). 169 After recruiting participants via certain criteria, the developed AI algorithm was tested against 170 the ground truth to assess the model's performance.

171

3.2 Population Characteristics

Yin et al was the only author to include healthy volunteers as the sole subject of his study (28). Alternatively, Garaiman et al was the only investigator to acknowledge limiting his study to include only diseased patients due to ethical consent considerations (30). The remaining eight studies included both diseased participants and normal controls (15, 29, 31, 32, 35, 40, 41, 55). Without including both normal and diseased subjects, an AI algorithm would not be capable of predicting abnormalities. The diseases addressed by each study are shown in **Fig. 2**.







Among the six studies investigating systemic sclerosis (SSc), three authors 181 considered two variants as the normal controls: completely disease-free healthy participants and 182 others with a common benign condition known as primary Raynaud's phenomenon (31, 35, 40); 183 also known as Raynaud's disease (PRD) (56). Conversely, Garaiman et al and Tello et all were 184 satisfied with PRD only as normal controls (15, 29, 30). Interestingly, despite the recognized 185 186 significance of disease duration due to its pathological impact on the body, and, consequently, 187 the outcomes assessed by NFC, only three authors (40, 41, 55) reported the disease duration of 188 their respective participants.

189 Participants' demographics were surprisingly not addressed in 50% of the studies (15, 28, 29, 32, 35). Moreover, only Kassani et al and Shah et al reported racial backgrounds, and 190 thus, shedding light on a very significant - yet overlooked - factor: skin tone (41, 55). This 191 192 finding highlights a significant gap in addressing imbalances due to a particularly relevant factor 193 like skin-color, in addition to generally important variables such as sex, age, and other co-194 morbidities, that may influence the algorithm's learning and output. Among all studies that investigated adults, Kassani et al was also unique in investigating a condition prevalent in the 195 children's age group, juvenile dermatomyositis (JDM) (41). 196

197 **3.3 Sample Sizes**

The highest sample size was 17,126 images obtained from 289 participants, as reported by Garaiman et al (30); which was more than three times the second highest sample size of 5,236 from 120 participants reported by Shah et al (55). Liu et al developed his algorithm with the least sample size of 50 images (32). **Fig. 3**Error! Reference source not found. shows a c omparison of the total sample sizes of both images and participants across all included studies.



Fig. 3 Comparison of the total sample sizes across all included studies shown in logarithmic scale

203

Authors differed in their approach to obtaining sample images from participants, and 204 in how balanced the normal controls and main study groups were. For instance, five authors 205 206 obtained multiple images from multiple sections of multiple nailfolds spanning multiple encounters (28, 30, 31, 41, 55). Conversely, both Liu et al and Murray et al obtained a single 207 image per participant (32, 40). However, Murray's image is a mosaic, which is a panoramic 208 wholesome image of the entire nailfold, compared to Liu's single image that represents a section 209 of the nailfold. Nonetheless, Liu et al used a data augmentation technique to generate a much 210 211 bigger sample size, derived from the original 30, that reached 20,664 images (32). Alternatively, Tello et al chose images at random from a bigger pool of a previously prepared dataset without 212 reporting the number of participants (15, 29). Similarly, Berks et al used 990 mosaics without 213 214 reporting the number of fingers, participants, or encounters that contributed to that dataset (35). Finally, Kassani et al had a sample of 1,441 images for their diagnosis model and a different 215 sample of 1,760 images for the predictive model (41). 216

217 **3.4 AI Algorithms Development**

218 **3.4.1 Model Architecture**

The majority of authors employed a deep learning model to accomplish their task (15, 28-32, 41, 55), except for Berks et al and Murray et al who utilized a pipeline of machine learning models (35, 40). All ten authors utilized a supervised machine learning approach where the input images were labelled with the ground truth so that the model learns through the inputoutput pairs.

Table *3* summarizes the different architectures for each algorithm, learning approaches,
diagnostic models' development and performance.

The nature of tasks performed by the algorithms varied as well. The first approach 226 227 employed by both Yin et al and Liu et al was a 'segmentation-based' object detection for 228 capillaries (28, 32). Liu et al relied on a pixel-wise semantic segmentation to decide whether it 229 belongs to a capillary or not (32), while Yin et al took a more global prospective to detect a capillary in the image rather than detecting it at the pixel-level (28). Four authors adopted the 230 second approach of 'classification' that aimed to classify the input image into one category out 231 232 of two or more categories/classes; either at the pixel, capillary, image, or global levels (30, 40, 41, 55). The remaining three authors took advantage of a multi-step mixed approach that relied 233 234 on detecting certain features first, then classifying them at one or more levels into the assigned 235 classes (15, 29, 31, 35).

2	3	6
---	---	---

Table 3 Comparing AI models across all ten studies

Features / Model Development voriablac Ground	Ground Ground	Model Development	lel Development	ent		Diagnost	Output ic Model		Results
used Truth Training Validation Testing	Truth Training Validation Testing	Training Validation Testing	Validation Testing	Testing		Image level	Global level	Predictive as well	
Capillary detectionCalculation by detection200 High QualityThe remaining splitQand density3 expertsimagesTr:V:T as 6:2:2e	Calculation by Quality The remaining split Quality Tr: V: T as 6:2:2	200 High The remaining split Quality Tr:V:T as 6:2:2	Q The remaining split Tr:V:T as 6.2:2	Q 66:2:2	0 - 1	uantitative (capillary count and density)	N/A	No	Average Precision 85.2%, AUPRC 85.2%
Clinical Status through chart Images as a whole + DMClinical Status through chart 5-fold cross validation applied to each of the 5 defining criteria for each diagnosesNot done. Relied on mean of all 5 testing sets	Clinical Status through chart review using specific defining criteria for each diagnoses testing sets	5-fold cross validation applied to each of the 5 all 5 diagnoses testing sets	<i>Not done.</i> s validation ach of the 5 all 5 noses testing sets	Not done. Relied on mean of all 5 testing sets		Qualitative	Yes, Qualitative	Yes. To predict a history of CV event in DM patients	For DM: 0.82 Recall, 0.84 AUROC 0.84 AUPRC
Enlarged, Giant Giant derived labels capillaries, Capillary Micro- Micro-Majority vote- 5-fold cross validation. The original dataset was split randomly into 5 equal dataset was split randomly into 5 equal forus. Tr:V:T was 3:1:1, repeated 5 practicing times until every group had the chance to be in each set	Majority vote- derived labels5-fold cross validation. The original dataset was split randomly into 5 equal dataset was split randomly into 5 equal groups. Tr:V:T was 3:1:1, repeated 5 times until every group had the chance ts	5-fold cross validation. The original dataset was split randomly into 5 equal groups. Tr:V:T was 3:1:1, repeated 5 times until every group had the chance to be in each set	s validation. The original split randomly into 5 equal V:T was 3:1:1, repeated 5 very group had the chance be in each set	e original nto 5 equal epeated 5 the chance		Qualitative (SSC pattern or not)	N/A	No	AUROC 85.07 – 92.6% and Recall of 81.91% - 92.61%
Apex detection, Mean shapeApex Group AHalf of The Group AAll 132 high-resMean shape score, score, as SSc or andClinical Status = 456Half of fingh-resAll 132 high-resMean shape score, and andClinical Status = 456Emaining of gr. B + from for bowAll 132 high-resApical width and bensityNormal figh- of high- group AFigh- from for bowAll 132 high-res	Clinical Status as SSc or Normal of high- resolution Early The high-res as SSc or Normal of high- stremaining of gr.B + 66 low- 66 low- group A res from gr.C	Half of Group A = 456 mosaics = 455 tremaining of gr.B + for b for low- for	The All 132 The high-res mosaics 455 from 66 low- group A res from gr. C	All 132 high-res mosaics of gr.B + 66 low- res from gr. C		Quantitative (count, densityetc.) AND Qualitative (SSc pattern or Normal)	Yes, using average measurement s from all fingers	No	AUROC 97% (B), 95% (C). Recall of 915 (B), 78% (C)
Images as a whole with ~ 28,000Known clinical status training and testing sets70 HC and 217~ 28,000of the patient in the registry.Data was divided into training and testing sets based on a 5-fold cross- validation70 HC and 217	KnownData was divided into70 HCclinical statustraining and testing setsand 217of the patientbased on a 5-fold cross-aJDMin the registry.validationimages	Data was divided into70 HCtraining and testing setsand 217based on a 5-fold cross-aJDMvalidationimages	ivided into testing sets and 217 5-fold cross- ation images	70 HC and 217 aJDM images		Qualitative (presence of JDM or not)	Yes, if ≥ aggregate predictions from all pictures the	Yes. Scores to JDM activity vs no activity	Recall 0.85, Precision 0.95, AUROC 0.93

		W	odel Developm	lent		Dutput		
Features / variables	Ground				Diagnostic M	lodel		Results
used	L ruth	Training	Validation	Testing	Image level	Global level	rredictive as well	
Abnormal shape, giant, dilation tortuosity, Microhemorr hages	A consensus of ≥ 3 and \geq 4 out of 5 NFC experts	85% of 1	the dataset	15% of the dataset	<i>Quantitative</i> AND Qualitative	N/A	No	>89% Specificity and NPV for all categories
 Detecting capillaries by their shape, and size	Validated manual annotation by experts	85% of the images v manually a validated co multiple m	dataset (2,306 vith 12,352 mnotated and apillaries with easurements)	15% o the dataset (407 images with 1,690 capillary)	<i>Quantitative</i> AND Qualitative	N/A	No	Mean Recall 85%, mean Precision of 72%
Detection of pixels that entail a capillary	Labels marked by a professional	On 30 NFC images *	On 20 NFC	C images	Qualitative (whether each pixel is a capillary or not)	N/A	Ň	Mean Accuracy 91.72%, mean dice score 97.66%
Capillary detection, apical width, orientation, tortuosity	Labels marked by a professional	80 images with 450 training RoI	456 images (104 HC, 83PRD and 268 SSc)	455 images (104 HC, 83 PRD and 268 SSc)	Quantitative (capillary count and vessel morphology measurements)	N/A	No	80.9 Recall, 64.1 Precision, F-measure of 71.5
Inter- capillary distance, width, tortuosity, derangement	Clinical diagnosis	Randomly and testing classifiers F	split the dataset i g. Used a linear s for training . Re process > 60 trial	into training set of SVM peated that Is	<i>Quantitative</i> AND Qualitative	N/A	Ňo	Pearsons Correlation 75% correct match.

- 238 N/A = No available data or not reported by author, Tr:V:T = Training:Valdation:Testing, HC = Healthy
- 239 Controls, aJDM = active Juvenile Dermatomyositis, * Data augmentation was used to generate 20,664
- 240 images, RoI = Region of Interest, PRD = Primary Raynaud's Disease, SSc = Systemic Sclerosis, DM =
- 241 Diabetes Mellitus, CV = Cardiovascular, NPV = Negative Predictive, Value.
- 242

243 **3.4.2 Model Input**

244 Pre-analysis processing to optimize the model performance was carried out either manually, automatically, or semi-automatically and reported in varying detail in six studies (15, 245 31, 32, 35, 40, 41). It included simple tasks such as sorting the images into "acceptable" or 246 "unusable" quality, rescaling the image resolution or size to a certain value, flipping, inversion, 247 248 rotation, or brightness and noise-level adjustment. It also encompassed more complex tasks such 249 as feature engineering to fuse multiple images of the same nailfold into a one panoramic 250 'mosaic', selection of the Region of Interest (RoI), marking of certain 'landmarks' on the image, 251 or calculation of certain measurements to draw graphs that would later serve the model. Eight studies reported the exact features to be extracted or calculated to be used by 252

the model in the segmentation/classification task (15, 28-32, 35, 40). As outlined in

Table 3, capillary detection itself appears to be the most frequently used feature, as it serves as foundation for detecting and/or calculating other metrics such as: capillary count/density, intercapillary distance, capillary loss, apical width, enlargement, orientation, tortuosity, and derangement. On the contrary, Kassani et al and Shah et al relied on their deep learning models to find their own patterns to successfully classify NFC images, with Kassani's model providing a visual explanation for its prediction (41, 55). **Fig. 5** depicts the process flow starting from image acquisition until the final output by the AI model is produced.

3.4.3 Ground Truth Determination

262 Clinical status of the participant as recorded in the registry of the dataset, or charts of 263 electronic medical records, was used as the benchmark by four authors (31, 40, 41, 55). Although this method eliminates a lot of subjectivity associated with manual labelling by experts and looks 264 265 more pragmatically at the entire process through the final end-goal, it is potentially biased with 266 documentation errors of a single expert opinion and lacks the more reliable conclusions of multiple observers. That particular downside provided grounds for the remaining authors to 267 depend on expert annotations or labelling, whether at the capillary level or image level for 268 ground truth determination (15, 28-30, 32, 35). They differed in the number of experts recruited 269 270 (one to five experts) and in the background of the experts, whether a general NFC technician, a vascular specialist, an internal medicine physician, or a rheumatology specialist who was either a 271 young resident or an experienced attending. Even so, the number of experts per se made a 272 273 difference. For example, an odd number of 3, as implemented by Yin et al, made it easier to consider a decisive majority-vote in cases of disagreement (28). On the other hand, Tello et al 274 275 who relied on 5 experts reported significant interobserver disagreement that was achieved in a 276 non-negligible number of images (29). Authors calculated the accuracy, sensitivity and 277 specificity of expert's consensus and used these values as thresholds to compare the model's performance against (30, 31, 40). 278

279

280 3.4.4 Training, Validation and Testing

It is essential to distinguish between three different terms that entail model development: training, validation, and testing. 'Training' refers to the main process by which the model "learns" to perform its task, usually through multiple iterations known as epochs.

²⁸⁴ 'Validation' usually refers to the process of internal validation, also known as *reliability testing*, ²⁸⁵ in which the model's 'knowledge' is tested, like a mock exam. Finally, 'Testing' refers to the ²⁸⁶ actual assessment of the model's performance on a set that the model was never exposed to ²⁸⁷ before. Conducting model testing adds more objectivity when measuring the model performance ²⁸⁸ to compare it against other models, or to the gold standard. Authors varied considerably, as ²⁸⁹ shown in

Table 3 Comparing AI models across all ten studies their approaches to splitting the dataset into
Training: Validation: Testing (Tr:V:T) for model development and in their interchangeable usage
of the terms validation and testing.

Three authors explicitly stated using *k*-fold cross-validation in their models (30, 41, 293 55). Shah et al used 5-fold cross-validation so that each random set is used 4 times for training 294 295 and one time for testing by the end of the fifth round. This process was repeated for each of the 5 296 diagnoses (classes). They did not include additional testing using a separate dataset and they 297 used the mean values from all 5 testing sets to be considered the final testing result (55). 298 Garaiman et al also used a variation of 5-fold cross-validation where the original dataset was randomly divided into 5 equal-sized subsets so that Tr:V:T was done in the ratio of 3:1:1. This 299 process was repeated 5 times until each subset had the chance to be in each set. Garaiman also 300 had a separate dataset of 464 images that was randomly selected from the first validation 301 subsample to test the model's performance against manual labeling by experts (30). Finally, 302 303 Kassani et al split the main dataset of 1,441 into stratified 5-fold cross-validation for both training and validation. Then a separate data set of 287 of both normal and abnormal images was 304 used for testing the model (41). 305

Bharati et al separated the original dataset into 3 groups. Group A included highresolution mosaics from 10 fingers, half of which was used for training and the other half for validation. Groups B (high-resolution mosaics from 10 fingers) and C (low-resolution mosaics from 4 fingers) were used for the final testing of the model. Thus Tr:V:T was approximately 9:9:4 (31). Yin et al first isolated 200 high-quality normal images to train the model, then the remaining 1,588 were divided into Tr:V:T as 6:2:2 (28). Conversely, Tello et al divided the dataset into 85% for training and validation, and 15% for testing in both studies (15, 29).

Liu et al divided the dataset into 60% training (30 images) and 40% testing (20 313 images) and compensated for the small sample by generating 20,664 images for training, from 314 the original 30, using a data augmentation technique (32). Berks et al extracted 450 RoIs for 315 training out of a relatively small sample of 80 mosaics. An additional set of 910 images in the 316 317 dataset was split into two equally balanced sets representing all three classes; one half for 318 internal reliability and the other for final testing (35). Finally, Murray et al split a dataset of 116 mosaics randomly into training and testing sets. Then, they utilized a set of linear support vector 319 machine classifiers to train the model based on their labels and the associated features (40). 320

The methodology varied significantly between authors owing to the difference in model architecture, type of learning, balance/imbalance in the datasets, pre-processing analysis techniques, layers of networks in the model, single vs. multi-phase flow between these layers, whether feature detection was first needed before processing, and the quantitative or qualitative nature of output of the model. (15, 28-32, 35, 40, 41, 55). Additionally, authors varied in reporting the specifications of hardware and software used.

327 **3.5 Models Performance**

328 **3.5.1 Nature of Output**

Three authors presented their model output solely in qualitative terms (30, 32, 55). 329 330 Shah et al had the model classify the image out of 5 classes representing healthy status, and four different disease states (55). Gariaman's classification of the image was binary as either diseased 331 or non-diseased (30). Liu et al analyzed the image at the pixel level to classify whether it belongs 332 to a distal capillary or not, so that in the end it presents a binary pixel map showing capillaries or 333 334 their absence (32). In contrast, two authors reported solely quantitative reports. Berks et al 335 reported capillary count and vessel morphology (35). Yin et al identified capillary count and 336 density (28). Lastly, the remaining five studies combined both qualitative and quantitative results 337 (15, 29, 31, 40, 41).

These results were majorly presented at the image level. Only three authors have also presented their results at the global, or participant-level (31, 41, 55). Bharati et al averaged measurements from multiple mosaics of multiple fingers to give a subject-level probability at a single visit (31). Alternatively, Kassani et al considered an aggregate value of \geq 50% to be the threshold to consider a patient-level prediction successful (41).

Lastly, in addition to the main diagnostic model, only Kassani et al and Shah et al had presented a second predictive model that provided additional clinically useful information beyond merely diagnosing the presence or absence of the disease (41, 55). Kassani's predictive model aimed to provide a score for disease activity, which translates to its future severity (41). Similarly, Shah's model predicted a history of a complication (cardiovascular event) in patients with the disease using only the NFC images and the disease status of that particular patient (55).

349 **3.5.2 Reporting Metrics**

350 Standardized metrics commonly used in computer vision to asses detection of 351 objects (57) overlap with similar metrics commonly used in medicine to describe the 352 performance of diagnostic tests. They usually entail a confusion matrix that shows the predicted 353 against the actual positives and negatives. From those values, many indices can be calculated such as sensitivity, also known as *recall*, specificity, positive predictive value, also known as 354 precision, negative predictive value, and accuracy. Certain graphs that efficiently demonstrate 355 the effectiveness of these models are generated from these metrics and indices, such as Area 356 Under the Receiver Operating Curve (AUROC) and Area Under the Precision Recall Curve 357 358 (AUPRC). Other metrics reported included Intersection over Union (IoU), F1-scores, Pearson-Correlation, and Dice-scores. The lack of standardization of reporting presents a challenge to 359 compare the performance of these models, which is an expected hindrance, give the novelty of 360 361 this subject. It's highly recommended that a unified approach be presented for future research so that progress can be made. However, for the purposes of this review we present below some of 362 363 the significant results as reported by their respective authors.

Recall was reported in 7 studies, either for the final model's ability to classify an 364 365 NFC image or regarding a feature per se (15, 29-31, 35, 41, 55). It ranged from 93.87% by Garaiman et al in detecting "giant capillaries" (30) down to 70.5% by Berks et al when the 366 model's ability to 'detect capillaries' was compared with observer no.2 as the ground truth (35). 367 Precision was reported in 5 studies (15, 28, 29, 35, 41). It's highest value of 0.95 at bootstrapped 368 369 confidence interval (CI) of 95% was reported by Kassani et al in classifying JDM patients from healthy controls at the image level (41). Berks et al reported the lowest precision of 51.7 in 370 detecting capillaries when observer no.2's labels were used as the ground truth (35). Specificity 371

372 was reported in 5 studies (29-31, 41, 55). Bharati et al reported the highest specificity of 91% for detecting a SSc pattern in high-resolution images of group B from normal controls (31). While 373 374 the lowest value of 62.2% was reported by Garaiman et al for detecting microhemorrhages (30).

Accuracy was reported in 4 studies only (30, 32, 35, 41). Berks et al reported the 375 highest accuracy of 93.6% in differentiating distal from non-distal capillaries when the ground 376 377 truth was determined by consensus of both expert observers (35). However, the lowest range of 378 accuracy of 85.5% - 93.5% was reported by Garaiman et al in delineating the presence of early, 379 active and late patterns of SSc (30). Area Under the Curve (AUC) was reported in 5 studies (28, 380 30, 31, 41, 55). The highest AUROC of 97% was reported by Bharati et al in predicting SSc patterns from normal controls in high resolution images of group B (31). Shah et al reported the 381 lowest AUROC of 0.84 in detecting diabetes (55). 382

383

3.5.3 General Descriptive Results

384 The time taken by the algorithm to produce the final output was not reported by most authors, except for Yin et al who reported 0.064 seconds for the capillary density calculation (28) 385 386 and Garaiman et al who stated that a report can be generated for each patient with 16 images in 387 \sim 3 seconds; given that labelling 1 image takes 0.19 seconds (30). Kassani et al reported the time 388 it takes to train 1 epoch of the model but not the final time elapsed, including any pre-analysis processing time elapsed (41). 389

390

The overall performance of all models is summarized in

Table 3. Compared to the gold standard of manual experts labelling these models have demonstrated equally consistent performance with faster timing (28, 35), or better detection of features (30), or patterns (55). Several models outperformed other AI algorithms such as YOLO5 (28), MobileNet (41), U-Net and ResNet (32).

Some models were tested in less than ideal conditions, such as low-resolution images (31), or under different lighting conditions (28) to mimic real-life scenarios were the image acquisition process will not yield high-quality images yet the model would still be able to function effectively. Two authors reported lower performance of their models compared to experts in certain areas and they discussed possible explanations for such differences (29, 30). Finally, it is worth noting that Tello et al was the only author to do an external validation study of the previously developed algorithm at capillary.io (29).

402

403 **DISCUSSION**

To answer the proposed research questions, we sought to discuss the findings of this review in four sections; given the wide variation in variables contributing to NFC analysis. Section-I lays the background by presenting the NFC technique and its significance in medicine. Section-II addresses the challenges facing the current methodology. Section-III presents the solutions AI offers to overcome said challenges. Finally, Section-IV compiles some considerations for future directions.

410 Section I: NFC Technique and It's Significance in Medicine

411 I - 1 Rationale and Premise of NFC

412 NFC is a simple non-invasive technique that looks at the microcirculation in the413 fingers. Arterial blood carrying nutritive oxygenated blood from the heart recaches one of its

final destinations at the distal end of fingers/toes. NFC observes nailfolds closely through a 414 microscope to clearly visualize the terminal capillary networks. The distal row of capillaries is 415 416 seen as a convex hairpin loop that turns around to eventually form venules that carry the waste products away from tissues and back to the heart (1). This healthy microenvironment is tightly 417 regulated and maintained so that significant changes to the capillaries array or morphology do 418 419 not develop over a short period of time (3). Accordingly, chronic pathological conditions 420 eventually distort the normal homeostasis and induce microvascular changes revealing the long-421 standing tissue damage (2). Examples of such systemic conditions affecting the whole body 422 where NFC findings were correlated to disease status or progression include many rheumatological diseases such as Systemic Lupus Erythematosus (SLE) (10, 11, 58), Systemic 423 Sclerosis (SSc) (9, 25, 59-61), Ankylosing Spondylitis (AS) (62), inflammatory diseases such as 424 vasculitis (63-65), Idiopathic Inflammatory Myopathies such as polymyositis and Juvenile 425 426 Dermatomyositis (JDM) (6, 41), inflammatory arthritis (66), dermatological such as 427 dermatomycosis and psoriasis, and finally components of metabolic syndrome such as diabetes (55) and hypertension (32). 428

429 I - 2 Advantages and Significance in Medicine

NFC offers countless perks to detect such systemic manifestations. Most 430 importantly, is the fact that it's a non-invasive procedure that yields very valuable information 431 that can help in the diagnosis, prognosis, staging and follow up of patients Additionally, the 432 equipment needed is relatively cheap, and mobile, guaranteeing broad accessibility for healthcare 433 434 facilities. Not only that, but the NFC technique to obtain images is by itself user friendly and easy to implement. Coupling such perks with a considerable reliability in the manual analysis of 435 436 NFC images has rendered the technique the gold standard in assessing nailfold capillaries (67).

To illustrate the significance of NFC, studies of abnormal changes in the nailfold 437 capillaries were found to be associated with skin involvement and duration of untreated JDM 438 (68, 69). Likewise, abnormal NFC changes constitute two out of the nine scoring points to fulfill 439 the 2013 ACR/EULAR classification criteria of SSc (70) and is important in stratifying SSc 440 patients into early, active and late (71-73). 441

442 It is also used to differentiate between types of Raynaud's Syndrome (RS). RS is an episodic color change in the fingers with or without pain in response to cold. It can present as a 443 444 primary benign condition with no evidence of an underlying disease, known as Primary 445 Raynaud's Syndrome OR Raynaud's disease (PRD). Or it can be a secondary symptom associated with other medical conditions, like SSc (56), one of the most common causes of 446 Secondary Raynaud Syndrome or Raynaud's phenomenon (SRP). Trombetta et al found that a 447 quantitative change in the capillary diameter is predictive of progression of PRD into SRP (17). 448 Dolijanovic et al followed a cohort of 250 PRD patients over six years and found that most 449 450 participants had normal findings with only 10 out of all subjects (4%) would show SSc pattern 6 months before expressing a particular disease (74). Although, this study concluded a 451 considerable lack of reliability in predicting future progression to certain diseases from such non-452 453 specific capillary changes in that study population, it did highlight an important finding, and that is if a SSc pattern was found, it would highly correlate to future development of SSc with high 454 455 specificity and precision.

I - 3 Preprocedural Preparation 456

457 Before the procedure, participants are prepared by avoiding caffein, smoking, stress, and cosmetic procedures on fingers/toes for about 3 weeks before the test day. Then, they are 458 seated in an upright position where the heart is at the level of the nailfold, in a quiet room with a 459

stable temperature of >20 °C for about 15-20 min to provide heat adaptation and endure mental
comfort. Next, the nails are cleaned, and an immersion oil is applied to improve visibility and
translucency by reducing diffuse reflections (75).

The apparatus is then set after deciding the following key aspects. The model and type of the capillaroscopy device is determined and whether it will be fixed or hand-held. Then the magnification is set depending on the camera resolution, its angle and physical distance from the nailfold (contact vs on-contact). Note that calibration to account for such distance might be required; either manually or automatically. Next, the finger/toe to be examined is placed and the light source, its intensity and angle are adjusted for optimal brightness and least reflections.

469

I – 4 NFC Image Acquisition

Traditional NFC relies on a camera to capture photos of the nailfold. NVC is an updated alternative that records a video instead, then extracts screenshots of frames with good capillary visibility. Some authors like Murray et al described a software that allowed highmagnification panoramic mosaics to be constructed from a video without movement artifacts (40). After images are obtained, they might be manipulated and *pre-processed* to varying degrees, either manually, or using additional software, before they are finally fed into the AI model.

477 Section II: Current Challenges Facing the Manual Approach

The current golden standard encounters several significant challenges, owing to the sheer variance in variables and circumstances required to obtain NFC images and analyze them. We also comment on how certain authors have approached that area and consider how AI can potentially overcome these obstacles.

482 **II – 1. Lack of standardization of the procedure (technique homogenization)**

483 II – 1.1 Preprocedural Matters

484 Starting with patient selection, most studies were unsuccessful in reporting 485 significant demographics related to the selected sample. At the top of the list, differences in skin 486 tone and pigmentation. This vital factor could point towards a potential bias in acquiring images 487 of fair-skinned participants only or in the reliability and validation of the technique itself in dark-488 skinned patients, propagating error to be carried forward when training and developing the 489 Machine Learning (ML) or Deep Learning (DL) models. With regards to the detailed 490 technicalities of patient preparation before image acquisition, only Garaiman et al intentionally 491 stated referring to the international Delphi consensus described by Ingegnoli et al (75); taking a 492 step forward towards unifying the pre-procedural setting.

Consider the two following apparatuses that were described by some authors: a 493 494 contact hand-held Optilia capillaroscope versus a non-contact fixed Dino-Lite microscope. The 495 first setup permits a broader-angle adjustment and higher zoom to improve visualization, but it runs the risk of unsteady operator hands, and thus image blur due to movement artifacts. On the 496 497 contrary, the second setup eliminates movement artifacts and can provide a more panoramic view of the entire nailfold, yet it requires higher magnifications and resolution to compensate for 498 499 the increased distance between the camera lens and the nailfold surface. Low magnifications such as 50x taken by dermatoscopes can provide a broader view of the nailfold, but are not 500 detailed enough to reliably discern capillaries when compared to the more ideally desired 501 magnification of 200x (76). 502

A capillary's morphology varies between hands and feet, finger to finger, and even central to peripheral nailfold sectors (77). According to Cutolo et al, the gold standard technique is to capture at least two adjacent fields of 1mm in the center of the nailfold at 200x (76).

506 Dinsdale et al reported that examination of all 8 fingers is needed, excluding thumbs. Otherwise 507 missing some abnormalities will reduce sensitivity(78). Conversely, Murray et al reported high 508 model performance using only the 4th (ring) finger in the non-dominant hand (40).

509

9 **II – 1.2 Procedural Considerations**

510 Surprisingly, the duration of the whole process from image acquisition till final 511 output was not reported by many authors. The breakdown of training time, pre-processing time and execution time is also recommended to be reported in future studies to calculate the net time 512 elapsed. Considering how much time pre-analysis processing consumes, it's variation from 513 single simple tasks to complex multi-step editing might necessitate user expertise and training. It 514 515 is of vital importance that authors report the software used, its version, specifications and tasks performed so that appropriate comparisons can be concluded. For instance, shah et al fed the DL 516 517 model with images only, to receive the final output (55). On the contrary, Tama et al (79) and 518 Doshi et al (80) adopted complex multi-step approaches such as binarization, skeleton extraction and segmentation, and enhancement operations with alpha-trimmed filter to address non-uniform 519 520 lighting combined with an iterative rule-based skeletonization procedures.

Additionally, Other aspects are not agreed on unanimously, yet. For example, 521 522 AlGindya et al reported that according to the literature, the green channel of an RGB image shows high contrast between capillaries and the background (81), and therefore used the green 523 filtered images for input. Contrarywise, Liu et al relied on the greyscale because they found that 524 there were no significant differences between the greyscale and the green channel image (32). 525 526 Another example reported by Liu et al, is that they claimed vertical flipping of an image might change its semantic information in the object hierarchies, in contrast to the horizontal flipping 527 528 (82).

Finally, we emphasize the need to report the specifications of hardware used, in addition to the software. Such factors might be limiting in terms of computational costs, timing, and even critical decisions such as feeding multiple measurements as input versus relying on a single average value, hence determining the level of processing, pixel-wise, capillary level, or image level.

534 **II – 2. Image Ambiguity**

The ambiguity in images is usually a result of its poor quality and/or presence of 535 artifacts that could be due to a wide range of factors. Camera-related factors include low 536 contrast/resolution images (mostly in low-cost devices), high image noise, lighting issues such as 537 reflections on the oil, non-uniform lighting, and extremes of brightness. It could be due to 538 539 physical factors such as air bubbles in the immersion oil, dust on lenses, dirt on/in fingernails, or blurring due to movement of patient fingers during imaging or examiner's hand if it's a hand-540 541 held device. Lastly, such variance may be disease-related such as too much fibrosis as in the late 542 stages of SSc, or due to presence of non-delineable structures. Poor reporting and lack of 543 standardization in tolerance thresholds to all these procedural parameters will result in increased image heterogeneity and accordingly, higher interobserver variability that will eventually be 544 transferred to the ML model. 545

546 II – 3. The Subjective Nature of Analyses by Human Experts

547 Manual analysis of NFC images, whether by clinicians or trained personnel, exhibits 548 considerable subjectivity that massively influences the gold-standard technique as well as the 549 input to ML/DL models, and therefore their predictions. Firstly, *operator bias* is demonstrated 550 through their reliance on intuition to select fields, capillaries and in classifying them instead of 551 examining all capillaries in each image. It also manifests as rough estimates of features instead of

relying on accurate measurements and indices. Finally, numerous cognitive biases could develop if analysis is done, for example, right after reviewing a patient chart. Other expected shortcomings due to human operators include the need for training to raise expertise (23) in addition to user, owing to the time consuming tasks to identify, label structures, categorize them and calculate indices; especially when eight fingers are examined to maintain a high sensitivity (78).

558 Inter-individual variability is yet another significant aspect due to the multi-variable 559 nature of the task. Despite testing its reliability, high interobserver variability still poses a 560 considerable bias especially when images get less clear/more ambiguous (67, 83). Saez et al in the GEAS survey found considerable heterogeneity between capillaroscopy experts, particularly 561 when considering morphological differences and not just categorical normal versus abnormal 562 563 patterns (84). Similarly, Garaiman et al reported high agreements especially regarding giant capillaries and microhemorrhages, as well as regarding assessment of patterns (e.g. SSc Pattern), 564 565 but not very much regarding capillary loss and enlargement (30). Such high inter-rater variance presents a challenge, per se, when the performance of the algorithm is judged against experts as 566 the decision of which expert to be regarded as the benchmark is made. Thus authors like Tello et 567 568 al 2023 (85) and Garaiman et al (30) reported an acceptable decent performance by the algorithm despite most experts performing better than the algorithm. Furthermore, the agreement is not 569 570 only low with regards to the grading of each image, but also in selecting which areas to be 571 evaluated (35). That was the basis for a more standardized criteria called the 'fast track 572 algorithm' that was developed to help ease and standardize the grading process (60, 72, 86, 87).

573 II – 4. Lack of Agreement on Which Features to be Extracted?

574 Current practice only looks at the distal row of nailfold capillaries. Some general 575 features of a normal nailfold include a transparent skin with clearly visible capillaries, absent 576 pericapillary oedema, visible subpapillary venous plexus (in up to 30% of healthy people), and 577 similar-looking capillaries that are regular in arrangement, mostly straight and perpendicular to 578 the nailfold (88).

579 Most of the features considered for analysis are qualitative and they can be a singular 580 feature such as a U-shaped hairpin-convexity constituting the normal capillary morphology. Or it 581 could be the absence of singular features such as tortuosity, ramifications, neo-angiogenesis, 3-582 point crossing, non-convex tip, and hemorrhages. (89, 90).

An additional way of analysis is through a collection of certain features, known as a 583 pattern, that defines a certain abnormal condition from the normal population. For example, 584 585 Raynaud's Syndrome is an episodic color change in the fingers with or without pain in response to cold. Raynaud's syndrome can present as a primary condition with no evidence of 586 an underlying disease, known as Primary Raynaud's Syndrome OR Raynaud's disease (PRD). 587 Or it can be a secondary symptom associated with other medical conditions, like SSc (56), one 588 of the most common causes of Secondary Raynaud Syndrome or Raynaud's phenomenon 589 590 (SRP). To distinguish PRD from SRP, Mannarino et al (91) used the following pattern: altered arrangement of capillary loop, decrease in the number of capillaries, and abnormal ramifications. 591 592 Diagnosing SRP is significant because it is considered a reliable early parameter for diagnosing 593 early SSc that has been clinically validated. One important way of doing that distinction, according to Bharati et al is that if PRD are negative clinically and serologically, they are likely 594 595 normal (31).

Another very common and significant example relates to SSc. It is a potentially 596 lethal autoimmune disease characterized by 3 hallmarks: Microangiopathy, production of 597 disease-specific autoantibodies and deposition of extracellular matrix proteins resulting in tissue 598 fibrosis. (70, 92) The microangiopathy usually manifests as low capillary density, high capillary 599 dimensions (dilation or giant), and abnormal morphology and hemorrhage (73, 93, 94). Smith et 600 601 al defined SSc pattern as very low capillary density (<3 capilaries.mm), or the presence of giant capillaries (72). Murray et al added high tortuosity and derangement; that is disorganization in 602 603 the overall direction of capillaries (40).

The same disease, like SSc, could show different patterns across different stages of the 604 same disease, that is typically used to help monitor improvement or disease progression on 605 follow up. For example, early, active and late/severe patterns of SSc have been identified and 606 607 validated in clinical studies, commonly the one described by Cutolo et al and standardized by Smith et al. (17, 25, 95, 96). The importance of recognizing such patterns helps monitor disease 608 progression or improvement on follow up. This finding presents an opportunity for early 609 intervention before severe organ involvement could occur, or potentially predicting future 610 disease status. Finally, Other less understood non-specific set of features are as known as 611 612 disease-associated changes (15, 30, 85)

A few quantitative features have also been described such as avascular areas defined as distance between 2 loops > 500 μ m, that normally should be absent (88). Interestingly, it was demonstrated that calculation of the mean score of such capillary loss could be reliably reduced from 32 NVC images (four fields per finger for eight fingers of the patient analyzed) to eight NVC images (one field per finger for eight fingers of the patient analyzed). This finding can save

valuable patient time as well computational costs, stressing on the significance of disclosing allaspects of the process to help deduce such conclusions (97).

Another commonly calculated feature is capillary density (normally = 9-13 in 1 linear mm). Density is related to tissue perfusion and microvascular function. The less normal conditions are the lower the density. Finally, many measurements can be calculated for each capillary, including: arterial limb diameter, venous limb diameter, apical loop diameter (7) (normally < 20 μ m (25)) and total width. From these calculations, two important descriptions emerge, namely a dilated capillary (typically 20-50 μ m), or a giant/mega capillary (typically >50 μ m) (25) that are normally absent in a healthy individual.

627 II – 5. Lack of Standardization of such Features

628 II – 5.1 Defining a Parameter or Pattern

629 Unfortunately, the aforementioned features lack unanimous agreement on a validated 630 and clinically relevant definition. To demonstrate, let's consider the capillary density. Generally speaking, Neubauer et al described a normal density as 9-13 per linear mm (88), while Cutolo et 631 632 al relied on capillary loss as <7 capillaries per mm (98). Alternatively, in et al didn't rely on a 633 specific criteria and they rather compared their model's performance to that of the experts count 634 in normal healthy volunteers (28). On the other hand, Bharati et al were more specific in their 635 definition as they counted all capillaries from left-most to right-most within each mosaic image of the entire nailfold and divided that number by the distance in mm between the same left-most 636 to right-most (31). 637

Another variation lies in the approach to detecting a terminal capillary loop/apex in the distal line of capillaries to differentiate it from other detected vascular structures. For instance, some authors rely on the direct observation method compared to the 90° degrees

method described by Hosftee et al (67) and used by Yin et al (28). Alternatively, Karbalaie et 641 al developed the semi-automated Elliptic Broken Line (EBL) method (99). Recently, Bharati et 642 643 al used the fully automated deep learning model U-Nets for apex candidate generation, followed by ResNet34 for candidate classification (31). 644

The difficulties due to lack of such standardization is not unclear, as expressed by 645 646 Cutolo et al, regarding the reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases (89). In an attempt to overcome these differences some 647 648 authors proposed potential standards to be followed whether in defining a single parameter or a 649 pattern. For instance, Jones et al proposed a taxonomy for the morphology of nailfold capillaries (38). Neu-bauer Geryk et al described a possible standardized technique with proposed normal 650 values to define a normal for healthy subjects (88). Smith et also developed well-defined criteria 651 652 that was adopted by the EULAR society to describe normal ($\leq 20 \mu m$), dilated (20-50 μm), and (giant/mega >50 µm) capillaries (25). Smith et al and Cutolo et al attempted to standardize the 653 defining criteria for SRP in SSc and how it differs from PRD (25, 72, 73). Cutolo et al also 654 initiated a similar proposition for a different disease like SLE (11). 655

656

II – 5.2 Clinical Relevance and Validation of Features

Surely, studying these features without any clinical relevance considerations or 657 reliability testing will render the entire process purely academic and hinder its progression to a 658 practically applicable tool. Such studies will emphasize the 'more significant' features so that 659 they get assigned a higher weight. As an example, Trombetta et al found that a capillary diameter 660 of $> 30 \ \mu m$ is an independent predictor for the progression of PRD patients to SRP (17). 661 Similarly, capillary density was found to be a significant quantitative parameter in studies of 662 conditions like diabetes (100), connective tissue diseases, pulmonary hypertension in SSc 663

patients, and chronic kidney disease (99) that would relate to a particular aspect of these 664 diseases. Understanding the implications of this matter, the SCLEROCAP study by Boulon et al 665 was conducted to assess the reliability of Maricq and Cutolo's classification of capillaroscopic 666 features that can stage SSc patients, or rather predict their status (101). Accordingly, efforts to 667 propagate and disseminate the validation of these features should be encouraged to guide future 668 669 research in towards a more patient-oriented direction, whether these features were relating to the study of condition at hand, or other unknown conditions. Moreover, certain features might be 670 671 deliberately, and safely, ignored, like what Bharati et al did. They disregarded microhemorrhages 672 from being input into the model since they saw the difficulty to define it with lack of its relevance to diagnosing SSc (31). 673

For that reason, authors like Tullo et al (29) decided to detect a feature such as *tortuosity*, even though it had no current validating studies, to understand possible ways it could prove relevant. Typically, it has been looked at with a quantitative approach, calculating the percentage of tortuous capillaries to discern normal healthy individuals (<5%) from other conditions that could potentially manifest at certain higher cutoffs such as 40% or 70% (102).

....

679

II – 5.3 Decisions in Conflicting Matters

Defining hierarchical principles in labelling a capillary is an important step that needs to be addressed especially after these labels will be used to train ML models. For example, Tello et al (103) prioritized classifying a capillary as being 'giant' over 'tortuous', if both features were present in the same capillary. Additionally, Garaiman et al noticed sub-optimal consistency in NFC image labels owing to the simple fact the different attending physicians have analyzed images of the same patient at different time points, thus affecting the ground truth of the developed model (30). Another decision would arise if the feature at hand is not clearly

visualized. For example, Tello et al relied on the width of limbs as an acceptable alternative (incase the apical diameter wasn't clear enough) to detect dilated/giant capillaries(29).

Furthermore, when experts, and henceforth, ML models, aim to assign patient-level diagnoses, the approaches differ. For example, some experts would label a participant as abnormal if 'any' NFC image from anyone of the finger is labelled as abnormal. Conversely, Bharati et al averaged measurements from all participants to achieve global-level labelling (31), while Kassani et al considered a participant diseased if the aggregate from all pictures was \geq 50% (41).

695

Section III: How AI Is Solving These Challenges

696 III – 1 Evolution of AI beyond simple automation

697 Artificial Intelligence (AI) was first described as a term by John McCarthy in 1956 as the science and engineering of making intelligent machines. Despite the difficulty of defining 698 exactly the aspects of human thinking, rationalization and decision-making processes, AI aims to 699 700 simulate one or more of these complex processes, at least partly. Automation of any process 701 relies on algorithms which are mathematical operations or code, that can be simple or a multi-702 step series, that are fed a particular type of input to process in a precisely defined manner and 703 give a certain output. If it was given any new or unusual input that it's not programmed to 704 process, it will fail to deal with it. AI, however, is more than a simple automated code, that 705 performs 'smart' functions, in an attempt to mimic human reasoning. ML, which is a subtype of 706 AI, takes it a step further, by learning how to deal with new information on its own without much 707 prior programming, exactly like a human child learning. DL is a further subtype of ML that tries 708 to learn entirely on its own by interacting with its environment in certain ways and developing a 709 'brain' of its own that is a black box to its developer.

710 A common way of teaching these machines how to learn is the supervised approach through input-output pairs. In our case, this means showing the model a normal NFC image and 711 telling it that it is normal or showing it a particular feature and telling (labelling) it what it is. 712 Another would be to let the model figure out differences in input on its own by feeding it only 713 714 the images, known as unsupervised. Other methods employ a mixture of both include semi-715 supervised and reinforcement learning whether using a human agent in the loop or not. Although 716 ML is a smart enough machine that can do incredibly difficult tasks, DL models seem to look at 717 things through a 'fresh set of eyes' that offers an unparalleled and novel approach to analyses.

718 III – 2 Superiority of AI

Overcoming the challenges that come with NFC image ambiguity (as discussed in section II-2) had posed a huge obstacle for experts to interpret these images. AI models can detect minute structures that are invisible to the naked eye and find relations between an incredible number of parameters within a very short time frame. Such qualities allow it to circumvent such heterogeneities, or even edit them before analyses in a fully automated, and possibly real-time, manner.

725 AI has also eliminated a lot of (not all) the errors attributed to human operation. 726 Provided with decent hardware, an AI model can compute an insanely massive number of 727 parameters at the same time to produce a consistent more objective output within seconds, if not 728 less. Its training is less exhaustive and consuming compared to human training, and it would be 729 able to analyze so much more with less resources. Such capabilities can potentially present a 730 more objective output that relies on certain criteria, compared to human experts. As an example of how AI models can reduce operator bias, can be demonstrated as many experts usually rely on 731 732 their subjective intuition to select a few capillaries within a sector of an NFC image of a single

finger to classify it rough manner. An AI model, will instead look at all the capillaries in the entire nailfold of all fingers, take precise measurements and draw indices related to all of them, extract much more features and issue a more comprehensive and thorough judgment in a fraction of the time taken by experts. Not only that, but its output wouldn't be influenced by reading patient's charts, as might happen with experts.

Additionally, future predictions about the potential risk of developing a certain condition can be drawn. Current models have demonstrated the potential to fill the gap in identifying predictive features correlating to actual diseases progression (33).

741

Section IV: AI Considerations and Future Directions

742 IV -1 Current Limitations and Challenges

Thorough documentation and comprehensive reporting of the entire process, from patient selection and pre-procedural preparation to image acquisition and analyses cannot be overstated. It is essential to recognize that as long as humans exist, their biases will too. The question therefore becomes how to minimize propagating these biases to AI. For example, the scarcity of datasets in dark skinned population will render these AI models inefficient in performing the same task compared light-skinned populations.

Similarly, errors and biases in the preprocessing, as pointed out by Murray et al may shift towards a particular parameter more than others, and eventually skew the mode towards over/under estimations (40). Moreover, standardizing the measurement units' whether real or arbitrary will close the gap towards a more objective feature extraction and therefore, output. An additional drawback is the limited open-access datasets that newer models can use for training.

Condition-specific factors may also limit the predictive models' accuracy. For
example, Kassani et al reported difficulty in predicting JDM disease activity due to difficulty in

measuring disease quiescence (and limitations in doing so using the manual DAS itself, as it fails to sensitively capture disease activity compared to other recent biomarkers) and the fact the capillary damage may persist with inactive disease(41). That example enforces the fact that biases are carried forward with the AI, and that the burden of providing such answers falls on the developer, not the AI model. That is not to say that AI models don't share the burden of ethical responsibility to be explainable, but that it highlights the usually overlooked human bias.

762 **IV-2 The Future of AI in NFC**

AI models can be further enhanced by feeding them with more information that just an NFC image, such as a patient's electronic medical record, similar to what Sheh et al did (55). Impressive results already established when NFC was fused with other modalities such as ultrasound (104, 105), doppler sonography (106), laser scanning microscopy(107), and optoacoustic imaging (108, 109).

768

769 CONCLUSION

770 AI models have demonstrated a truly remarkable potential as a clinical decisionsupportive tool. Owing to the novel nature of this technology, it is of the utmost significance for 771 772 authors to report future NFC-related studies in the most comprehensive way possible, 773 particularly population demographics and execution times. That is to overcome propagating human biases to AI models, standardize the NFC methodology and reporting metrics to allow for 774 comparisons and conclusions to be made. ML and DL models succeeded in producing a fully 775 776 automated and objective quantitative output that will form the basis for future prediction and patient-reported outcomes research. Fusion of NFC with other technologies like doppler laser 777 778 and optoacoustic imaging to enhance the extraction of features and the precision of measured

values will further increase the sensitivity and specificity of such tools to be very efficient in daily clinical practice. Future studies should focus on the deployment and provision of full functionality for these types of applications using explainable AI. Quality assessment standards and ethical considerations still present a big challenge in reporting and in testing the safety of these techniques. Finally, with more external validation studies across multiple different settings in different populations these tools will revolutionize diagnostics through NFC image interpretation.

786

787 **OTHER INFORMATION**

788 FUNFING AND CONFLICT OF INTERESET

789 The authors of this review declare no potential conflicts of interest regarding research,790 authorship, or publication. This review was not supported by any source of financial aid.

791 ACKNOWLEDGMENTS

- 792 Figure 1 was created using MS Word
- **Figures 2, 3 and 4** were created using MS Excel
- 794 **Figure 5** were created using MS Paint

795 **LEGENDS**

- **Table 1.** Research questions and their rationale.
- **Table 2.** Compares study design and population characteristics across all ten studies.
- **Table 3.** Compres AI model architecture, development and performance across all ten studies.
- **Fig. 1** A PRISMA Flowchart summarizing the process of acquiring the final included studies.
- **Fig. 2** Geographical distribution of the countries where included studies were conducted.
- **Fig. 3** Frequency of diseases addressed by the included studies.

- **Fig. 4** Comparison of the total sample sizes across all included studies.
- **Fig. 5** A summary of the whole process of NFC and AI analysis.

804 **S.1** Shows the risk of bias and quality assessment of all included studies using QUADAS 2.

805 **REFERENCES**

8061.Cracowski JL, Roustit M. Human Skin Microcirculation. Compr Physiol. 2020;10(3):1105-54.

Haggerty A, Nirmalan M. Capillary dynamics, interstitial fluid and the lymphatic system.
 Anaesthesia & Intensive Care Medicine. 2022;23(2):130-7.

809 3. Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell.
810 2014;54(2):281-8.

- 4. Goydin AP, Shutova SV, Fabrikantov OL. Evaluation of the diagnostic capabilities of nailfold
 capillaroscopy in diabetic retinopathy. Vestnik oftalmologii. 2023;139(1):16-26.
- Shah R, Petch J, Nelson W, Roth K, Noseworthy MD, Ghassemi M, et al. Nailfold capillaroscopy
 and deep learning in diabetes. J Diabetes. 2023;15(2):145-51.
- 815 6. Zisa D, Bloostein A, Jannat-Khah D, Cutolo M, Smith V, Fernandez D. Nailfold
- Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in
 Patients with Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology. 2022;74:3710-1.
- 818 7. Etehad Tavakol M, Fatemi A, Karbalaie A, Emrani Z, Erlandsson BE. Nailfold Capillaroscopy in
 819 Rheumatic Diseases: Which Parameters Should Be Evaluated? Biomed Res Int. 2015;2015:974530.
- 8. Cutolo M, Matucci Cerinic M. Nailfold capillaroscopy and classification criteria for systemic
 sclerosis. Clinical and Experimental Rheumatology. 2007;25(5):663-5.
- 9. Ingegnoli F, Gualtierotti R. A systematic overview on the use and relevance of capillaroscopy in
 systemic sclerosis. Expert Rev Clin Immunol. 2013;9(11):1091-7.
- 10. Marasco E, Duesing C, Keymel S, Zanframundo G, Codullo V, Sander O, et al. ANALYSIS OF
- 825 NAILFOLD CAPILLAROSCOPY FINDINGS AND CLINICAL FEATURES OF PATIENTS WITH
- 826 SYSTEMIC LUPUS ERYTHEMATOSUS AND PULMONARY ARTERIAL HYPERTENSION.
 827 Annals of the Rheumatic Diseases. 2023;82:1504-5.
- 828 11. Cutolo M, Melsens K, Wijnant S, Ingegnoli F, Thevissen K, De Keyser F, et al. Nailfold
- capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal.
 Autoimmunity Reviews. 2018;17(4):344-52.
- 831 12. Zeni S, Ingegnoli F. [Raynaud's phenomenon]. Reumatismo. 2004;56(2):77-81.
- 13. Matucci-Cerinic C, Nagaraja V, Prignano F, Kahaleh B, Bellando-Randone S. The role of the
- dermatologist in Raynaud's phenomenon: a clinical challenge. J Eur Acad Dermatol Venereol.
 2018;32(7):1120-7.
- 835 14. Smith V, Ickinger C, Hysa E, Snow M, Frech T, Sulli A, et al. Nailfold capillaroscopy. Best
 836 Practice & Research Clinical Rheumatology. 2023;37(1):101849.
- 837 15. Gracia Tello B, Ramos Ibañez E, Fanlo Mateo P, Sáez Cómet L, Martínez Robles E, Ríos Blanco
- JJ, et al. The challenge of comprehensive nailfold videocapillaroscopy practice: a further contribution.
 Clin Exp Rheumatol. 2022;40(10):1926-32.
- 840 16. Pauling JD. Could nailfold videocapillaroscopy usher in a new era of preventative disease-
- 841 modifying therapeutic intervention in systemic sclerosis? Rheumatology (United Kingdom).
- 842 2017;56(7):1053-5.
- 843 17. Amelia Chiara T, Vanessa S, Carmen P, Marianna M, Sabrina P, Caterina C, et al. Quantitative
- Alterations of Capillary Diameter Have a Predictive Value for Development of the Capillaroscopic
- 845 Systemic Sclerosis Pattern. The Journal of Rheumatology. 2016;43(3):599.

18. Kassani PH, Ehwerhemuepha L, Martin-King C, Kassab R, Gibbs E, Morgan G, et al. Artificial

intelligence for nailfold capillaroscopy analyses – a proof of concept application in juvenile

dermatomyositis. Pediatric Research. 2024;95(4):981-7.

849 19. Cutolo M, Trombetta AC, Melsens K, Pizzorni C, Sulli A, Ruaro B, et al. Automated assessment
850 of absolute nailfold capillary number on videocapillaroscopic images: Proof of principle and validation in
851 systemic sclerosis. Microcirculation. 2018;25(4):e12447.

Mazeda C, Silva S, Aguiar R, Barcelos A, Bastos JM. Correlation between arterial stiffness and
nailfold capillary microscopic abnormalities in systemic sclerosis: Results from a single centre crosssectional study. Artery Research. 2021;27:S22.

855 21. Nevskaya T, Baron M, Pope J. Criterion-related validity of european scleroderma study group
856 activity index in an early scleroderma cohort. Journal of Rheumatology. 2017;44(6):878.

22. Ornowska S, Chojnowski M, Felis-Giemza A, Dudek Ł, Olesińska M. Microvascular damage – a
marker of specific organ involvement in mixed connective tissue disease? Reumatologia. 2021;59(2):11520.

860 23. Herrick AL, Berks M, Taylor CJ. Quantitative nailfold capillaroscopy-update and possible next
861 steps. Rheumatology (Oxford). 2021;60(5):2054-65.

24. Cutolo M, Gotelli E, Smith V. Reading nailfold capillaroscopic images in systemic sclerosis:

863 manual and/or automated detection? Rheumatology (United Kingdom). 2023;62(7):2335-7.

Smith V, Herrick AL, Ingegnoli F, Damjanov N, De Angelis R, Denton CP, et al. Standardisation
of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic
sclerosis. Autoimmunity Reviews. 2020;19(3):102458.

26. Lenharo M. An AI revolution is brewing in medicine. What will it look like? Nature.

868 2023;622(7984):686-8.

869 27. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31870 8.

28. Yin H, Wu Z, Huang A, Luo J, Liang J, Lin J, et al. Automated nailfold capillary density
measurement method based on improved YOLOv5. Microvasc Res. 2023;150:104593.

Tello BCG, Ibañez ER, Comet LS, Del Castillo AG, Aznar CPS, O'Callaghan AS, et al. External
clinical validation of automated software to identify structural abnormalities and microhaemorrhages in
nailfold videocapillaroscopy images. Clinical and Experimental Rheumatology. 2023;41(8):1605-11.

30. Garaiman A, Nooralahzadeh F, Mihai C, Gonzalez NP, Gkikopoulos N, Becker MO, et al. Vision
 transformer assisting rheumatologists in screening for capillaroscopy changes in systemic sclerosis: an

artificial intelligence model. Rheumatology (Oxford). 2023;62(7):2492-500.

879 31. Bharathi PG, Berks M, Dinsdale G, Murray A, Manning J, Wilkinson S, et al. A deep learning
880 system for quantitative assessment of microvascular abnormalities in nailfold capillary images.
881 Rheumatology (Oxford, England). 2023;62(6):2325-9.

32. Liu S, Li Y, Zhou J, Hu J, Chen N, Shang Y, et al. Segmenting nailfold capillaries using an
improved U-net network. Microvasc Res. 2020;130:104011.

33. Urwin SG, Griffiths B, Allen J. Quantification of differences between nailfold capillaroscopy

images with a scleroderma pattern and normal pattern using measures of geometric and algorithmic
complexity. Physiol Meas. 2017;38(2):N32-n41.

887 34. Cheng C, Lee CW, Daskalakis C. A Reproducible Computerized Method for Quantitation of
888 Capillary Density using Nailfold Capillaroscopy. J Vis Exp. 2015(105):e53088.

Berks M, Tresadern P, Dinsdale G, Murray A, Moore T, Herrick A, et al. An automated system
for detecting and measuring nailfold capillaries. Med Image Comput Comput Assist Interv. 2014;17(Pt
1):658-65.

36. Gronenschild EH, Muris DM, Schram MT, Karaca U, Stehouwer CD, Houben AJ. Semi-

automatic assessment of skin capillary density: proof of principle and validation. Microvasc Res.2013;90:192-8.

37. Goffredo M, Schmid M, Conforto S, Amorosi B, D'Alessio T, Palma C. Quantitative color
analysis for capillaroscopy image segmentation. Med Biol Eng Comput. 2012;50(6):567-74.

- 38. Jones BF, Oral M, Morris CW, Ring EF. A proposed taxonomy for nailfold capillaries based on
 their morphology. IEEE Trans Med Imaging. 2001;20(4):333-41.
- 39. Hu Q, Mahler F. New system for image analysis in nailfold capillaroscopy. Microcirculation.
 1999;6(3):227-35.
- 40. Murray AK, Feng K, Moore TL, Allen PD, Taylor CJ, Herrick AL. Preliminary clinical
- evaluation of semi-automated nailfold capillaroscopy in the assessment of patients with Raynaud'sphenomenon. Microcirculation. 2011;18(6):440-7.
- 41. Kassani PH, Ehwerhemuepha L, Martin-King C, Kassab R, Gibbs E, Morgan G, et al. Artificial
 intelligence for nailfold capillaroscopy analyses a proof of concept application in juvenile
 dermatomyositis. Pediatric Research. 2023.
- 42. Liu PR, Lu L, Zhang JY, Huo TT, Liu SX, Ye ZW. Application of Artificial Intelligence in
 Medicine: An Overview. Curr Med Sci. 2021;41(6):1105-15.
- 909 43. Poon AIF, Sung JJY. Opening the black box of AI-Medicine. J Gastroenterol Hepatol.
 910 2021;36(3):581-4.
- 911 44. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
 912 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- 45. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an
 updated list of essential items for reporting diagnostic accuracy studies. Bmj. 2015;351:h5527.
- 46. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS:
 a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC
 Medical Research Methodology. 2003;3(1):25.
- 47. Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI
- statement: updated guidance for reporting clinical prediction models that use regression or machine
 learning methods. BMJ. 2024;385:e078378.
- 921 48. Sounderajah V, Ashrafian H, Rose S, Shah NH, Ghassemi M, Golub R, et al. A quality
- assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AI. Nature
 Medicine. 2021;27(10):1663-5.
- 924 49. Sounderajah V, Ashrafian H, Golub RM, Shetty S, De Fauw J, Hooft L, et al. Developing a
 925 reporting guideline for artificial intelligence-centred diagnostic test accuracy studies: the STARD-AI
 926 protocol. BMJ Open. 2021;11(6):e047709.
- 927 50. Collins GS, Dhiman P, Andaur Navarro CL, Ma J, Hooft L, Reitsma JB, et al. Protocol for
- development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic
 and prognostic prediction model studies based on artificial intelligence. BMJ Open. 2021;11(7):e048008.
- 51. Jayakumar S, Sounderajah V, Normahani P, Harling L, Markar SR, Ashrafian H, et al. Quality
 assessment standards in artificial intelligence diagnostic accuracy systematic reviews: a meta-research
- study. npj Digital Medicine. 2022;5(1):11.
- 52. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A
 Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine.
 2011;155(8):529-36.
- 936 53. Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH. MINIMAR (MINimum Information
 937 for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care. J Am
 938 Med Inform Assoc. 2020;27(12):2011-5.
- 939 54. Olczak J, Pavlopoulos J, Prijs J, Ijpma FFA, Doornberg JN, Lundström C, et al. Presenting
- 940 artificial intelligence, deep learning, and machine learning studies to clinicians and healthcare
- stakeholders: an introductory reference with a guideline and a Clinical AI Research (CAIR) checklist
- 942 proposal. Acta Orthop. 2021;92(5):513-25.
- 55. Shah R, Petch J, Nelson W, Roth K, Noseworthy MD, Ghassemi M, et al. Nailfold capillaroscopy
 and deep learning in diabetes. Journal of Diabetes. 2023;15(2):145-51.
- 56. Maciejewska M, Sikora M, Maciejewski C, Alda-Malicka R, Czuwara J, Rudnicka L. Raynaud's
 Phenomenon with Focus on Systemic Sclerosis. J Clin Med. 2022;11(9).
- 947 57. Zhu M. Recall, precision and average precision. 2004.

948 58. Schonenberg-Meinema D, Bergkamp SC, Nassar-Sheikh Rashid A, Gruppen MP, Middelkamp-949 Hup MA, Armbrust W, et al. Nailfold capillary scleroderma pattern may be associated with disease 950 damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up. 951 Lupus Sci Med. 2022;9(1). 952 59. Pawlik KK, Bohdziewicz A, Maciejewska M, Prado J, Czuwara J, Olszewska M, et al. evaluation 953 of cutaneous microcirculation in systemic sclerosis. An update. Przeglad Dermatologiczny. 954 2023;110(4):499-517. 955 Smith V, Vanhaecke A, Guerra M, Angelis RD, Deschepper E, Denton C, et al. Fast track 60. 956 algorithm: How to differentiate a scleroderma pattern from a non-scleroderma pattern. Annals of the 957 Rheumatic Diseases. 2019;78:1224-5. 958 Schonenberg-Meinema D, Bergkamp S, Nassar-Sheikh Rashid A, Gruppen M, Hak AE, Hissink 61. 959 Muller PCE, et al. Scleroderma pattern in nailfold capillaries of (childhood-onset) systemic lupus 960 erythematosus: Lessons from longitudinal follow-up. Annals of the Rheumatic Diseases. 2021;80(SUPPL 1):937. 961 962 62. Batko B, Maga P, Urbanski K, Ryszawa-Mrozek N, Schramm-Luc A, Koziej M, et al. Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved 963 964 by anti-TNF treatment. Sci Rep. 2018;8(1):13205. 965 Keret S, Mazzawi J, Slobodin G, Rimar O, Rosner I, Rozenbaum M, et al. Nailfold video 63. 966 capillaroscopy as a useful diagnostic tool in systemic vasculitis. Microvasc Res. 2022;143:104406. 967 64. Matsuda S, Kotani T, Wakura R, Suzuka T, Kuwabara H, Kiboshi T, et al. Examination of 968 nailfold videocapillaroscopy findings in ANCA-associated vasculitis. Rheumatology (Oxford). 969 2023;62(2):747-57. 970 Screm G, Mondini L, Confalonieri P, Salton F, Trotta L, Barbieri M, et al. Nailfold 65. 971 Capillaroscopy Analysis Can Add a New Perspective to Biomarker Research in Antineutrophil 972 Cytoplasmic Antibody-Associated Vasculitis. Diagnostics [Internet]. 2024; 14(3). Lambova SN, Müller-Ladner U. Capillaroscopic pattern in inflammatory arthritis. Microvasc Res. 973 66. 974 2012;83(3):318-22. 975 Hofstee HMA, Serné EH, Roberts C, Hesselstrand R, Scheja A, Moore TL, et al. A multicentre 67. 976 study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology. 2011;51(4):749-55. 977 978 Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile 68. 979 dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 980 2004;31(8):1644-9. 981 Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM. Association of normal 69. 982 nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile 983 dermatomyositis. Arthritis Rheum. 2010;62(5):1533-8. 984 van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 70. 985 classification criteria for systemic sclerosis: an American College of Rheumatology/European League 986 against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47. 987 71. Frank van den H, Dinesh K, Jaap F, Sindhu RJ, Murray B, Alan T, et al. 2013 classification 988 criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism 989 collaborative initiative. Annals of the Rheumatic Diseases. 2013;72(11):1747. 990 Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP, et al. Fast track 72. 991 algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmun 992 Rev. 2019;18(11):102394. 993 73. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of 994 microvascular damage in systemic sclerosis. The Journal of rheumatology. 2000;27(1):155-60. 995 Pavlov-Dolijanović S, Damjanov N, Ostojić P, Susić G, Stojanović R, Gacić D, et al. The 74. prognostic value of nailfold capillary changes for the development of connective tissue disease in children 996 997 and adolescents with primary raynaud phenomenon: a follow-up study of 250 patients. Pediatr Dermatol. 998 2006;23(5):437-42.

999 75. Ingegnoli F, Herrick AL, Schioppo T, Bartoli F, Ughi N, Pauling JD, et al. Reporting items for
1000 capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international
1001 Delphi consensus. Rheumatology (Oxford). 2021;60(3):1410-8.

- 1002 76. Smith V. When and how to perform capillaroscopy. Atlas of capillaroscopy in rheumatic
 1003 diseases: Elsevier; 2010. p. 33-42.
- 1004 77. Lambova S, Hermann W, Müller-Ladner U. Capillaroscopic Pattern at the Toes of Systemic
- Sclerosis Patients: Does It "Tell" More Than Those of Fingers? JCR: Journal of Clinical Rheumatology.
 2011;17(6).
- 1007 78. Dinsdale G, Roberts C, Moore T, Manning J, Berks M, Allen J, et al. Nailfold capillaroscopy—
 1008 how many fingers should be examined to detect abnormality? Rheumatology. 2019;58(2):284-8.
- 1009 79. Tama A, Mengko TR, Zakaria H, editors. Nailfold capillaroscopy image processing for
- 1010 morphological parameters measurement. 2015 4th International Conference on Instrumentation,
- 1011 Communications, Information Technology, and Biomedical Engineering (ICICI-BME); 2015 2-3 Nov.1012 2015.
- 1013 80. Doshi NP, Schaefer G, Zhu SY. An Evaluation of Image Enhancement Techniques for Nailfold
 1014 Capillary Skeletonisation. Procedia Computer Science. 2015;60:1613-21.
- 1015 81. Al-Gindy A, Al-Ahmad H, Qahwaji R, Tawfik A, editors. A novel blind image watermarking
- 1016 technique for colour RGB images in the DCT domain using green channel. 2008 Mosharaka International
- 1017 Conference on Communications, Computers and Applications; 2008 8-10 Aug. 2008.
- 1018 82. Li L-J. Semantic image understanding: from the web, in large scale, with real-world challenging
 1019 data: Stanford University, USA; 2011.
- 1020 83. Rodriguez-Reyna TS, Bertolazzi C, Vargas-Guerrero A, Gutiérrez M, Hernández-Molina G,
- Audisio M, et al. Can nailfold videocapillaroscopy images be interpreted reliably by different observers?
 Results of an inter-reader and intra-reader exercise among rheumatologists with different experience in
 this field. Clinical Rheumatology. 2019;38(1):205-10.
- 1024 84. Sáez-Comet L, Fanlo-Mateo P, Gracia-Tello B, Antonio Todolí Parra J, Freire-Dapena M,
- 1025 Espinosa-Garriga G, et al. Nailfold capillaroscopy in the Spanish Group of Systemic Autoimmune
- 1026 Diseases (GEAS). Results of an electronic survey. Medicina Clínica (English Edition). 2020;155(11):50910.
 10.
- 1028 85. Gracia Tello BC, Ramos Ibañez E, Saez Comet L, Guillén Del Castillo A, Simeón Aznar CP,
- 1029 Selva-O'Callaghan A, et al. External clinical validation of automated software to identify structural
- abnormalities and microhaemorrhages in nailfold videocapillaroscopy images. Clin Exp Rheumatol.
 2023;41(8):1605-11.
- 1032 86. Ng S-A, Tan WH, Saffari SE, Low AHL. Evaluation of Nailfold Capillaroscopy Online Training
 1033 Using the Fast Track Algorithm. The Journal of rheumatology. 2023;50(3):368-72.
- 1034 87. Sue-Ann N, Wen Hao T, Saffari SE, Low AHL. Evaluation of Nailfold Capillaroscopy Online
 1035 Training Using the Fast Track Algorithm. Journal of Rheumatology. 2023;50(3):368-72.
- 1036 88. Neubauer-Geryk J, Hoffmann M, Wielicka M, Piec K, Kozera G, Brzeziński M, et al. Current
- 1037 methods for the assessment of skin microcirculation: Part 1. Advances in Dermatology and
- 1038 Allergology/Postępy Dermatologii i Alergologii. 2019;36(3):247-54.
- 1039 89. Cutolo M, Melsens K, Herrick AL, Foeldvari I, Deschepper E, De Keyser F, et al. Reliability of
- simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases.
- 1041 Rheumatology. 2018;57(4):757-9.
- 1042 90. Karbalaie A, Emrani Z, Fatemi A, Etehadtavakol M, Erlandsson B-E. Practical issues in assessing
 1043 nailfold capillaroscopic images: a summary. Clinical rheumatology. 2019;38(9):2343-54.
- Mannarino E, Pasqualini L, Fedeli F, Scricciolo V, Innocente S. Nailfold Capillaroscopy in the
 Screening and Diagnosis of Raynaud's Phenomenon. Angiology. 1994;45(1):37-42.
- 1046 92. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the
- 1047 very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR
- 1048 Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476-81.

1049 93. Avouac J, Lepri G, Smith V, Toniolo E, Hurabielle C, Vallet A, et al. Sequential nailfold

videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis.
Semin Arthritis Rheum. 2017;47(1):86-94.

1052 94. Vanhaecke A, Cutolo M, Distler O, Riccieri V, Allanore Y, Denton CP, et al. Nailfold

1053 capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ

1054 involvement/progression? Rheumatology (Oxford). 2022;61(11):4384-96.

1055 95. Emrani Z, Karbalaie A, Fatemi A, Etehadtavakol M, Erlandsson BE. Capillary density: An
1056 important parameter in nailfold capillaroscopy. Microvasc Res. 2017;109:7-18.

Mihai C, Smith V, Dobrota R, Gheorghiu AM, Cutolo M, Distler O. The emerging application of
semi-quantitative and quantitative capillaroscopy in systemic sclerosis. Microvasc Res. 2018;118:113-20.

1059 97. Vanessa S, Filip De K, Carmen P, Jens TVP, Saskia D, Alberto S, et al. Nailfold capillaroscopy 1060 for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for 1061 disitel terratic leasing. A male of the Physical Physical 2011;70(1):180

digital trophic lesions. Annals of the Rheumatic Diseases. 2011;70(1):180.

- 1062 98. Cutolo M, Herrick AL, Distler O, Becker MO, Beltran E, Carpentier P, et al. Nailfold
- 1063 Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A
 1064 Multicenter, Prospective Cohort Study. Arthritis Rheumatol. 2016;68(10):2527-39.

1065 99. Karbalaie A, Abtahi F, Fatemi A, Etehadtavakol M, Emrani Z, Erlandsson B-E. Elliptical broken
1066 line method for calculating capillary density in nailfold capillaroscopy: Proposal and evaluation.

- 1067 Microvascular Research. 2017;113:1-8.
- 1068 100. Maldonado G, Chacko A, Lichtenberg R, Ionescu M, Rios C. Nailfold capillaroscopy in diabetes
 1069 mellitus: a case of neo-angiogenesis after achieving normoglycemia. Oxford Medical Case Reports.
 1070 2022;2022(9).
- 1071 101. Boulon C, Devos S, Mangin M, Decamps-Le Chevoir J, Senet P, Lazareth I, et al. Reproducibility 1072 of capillaroscopic classifications of systemic sclerosis: results from the SCLEROCAP study.

1073 Rheumatology. 2017;56(10):1713-20.

1074 102. Redisch W, Messina EJ, Hughes G, McEwen C. Capillaroscopic observations in rheumatic
 1075 diseases. Ann Rheum Dis. 1970;29(3):244-53.

1076 103. Tello BG, Ibáñez ER, Mateo PF, Cómet LS, Robles EM, Blanco JJR, et al. The challenge of
1077 comprehensive nailfold videocapillaroscopy practice: a further contribution. Clinical and Experimental
1078 Rheumatology. 2022;40(10):1926-32.

1079 104. Cafaro G, Venerito V, Valentini V, Bursi R, Perricone C, Gerli R, et al. COMBINED

1080 NAILFOLD CAPILLAROSCOPY AND ULTRASONOGRAPHY OF THE NAIL-ENTHESIS

1081 COMPLEX TO DISCRIMINATE PSORIATIC DISEASE FROM RHEUMATOID ARTHRITIS

- 1082 PATIENTS AND HEALTHY SUBJECTS. Annals of the Rheumatic Diseases. 2023;82:218-9.
- 1083 105. Nam K, Mendoza FA, Wessner CE, Allawh TC, Forsberg F. Ultrasound quantitative assessment
 1084 of ventral finger microvasculopathy in systemic sclerosis with Raynaud's phenomena: a comparative
 1085 study. RMD Open. 2023;9(1).
- 1086 106. Lüders S, Friedrich S, Ohrndorf S, Glimm AM, Burmester GR, Riemekasten G, et al. Detection 1087 of severe digital vasculopathy in systemic sclerosis by colour Doppler sonography is associated with 1088 digital places. Bhoumatology (Oxford) 2017;56(11):1865.72
- 1088 digital ulcers. Rheumatology (Oxford). 2017;56(11):1865-73.
- 1089 107. Yakimov BP, Gurfinkel YI, Davydov DA, Allenova AS, Budylin GS, Vasiliev VY, et al.
- Pericapillary Edema Assessment by Means of the Nailfold Capillaroscopy and Laser Scanning
 Microscopy. Diagnostics (Basel). 2020;10(12).
- 1092 108. Nitkunanantharajah S, Haedicke K, Moore TL, Manning JB, Dinsdale G, Berks M, et al. How
- 1093 well does deep learning differentiate between optoacoustic and optical nailfold capillaroscopy images
- from patients with systemic sclerosis versus those from healthy controls? Rheumatology (United Kingdom). 2020;59:ii79.
- 1096 109. Nitkunanantharajah S, Haedicke K, Moore TB, Manning JB, Dinsdale G, Berks M, et al. Three-
- dimensional optoacoustic imaging of nailfold capillaries in systemic sclerosis and its potential for disease
 differentiation using deep learning. Sci Rep. 2020;10(1):16444.